Eisai Zukünftiges Wachstum

Future Kriterienprüfungen 1/6

Eisai wird ein jährliches Gewinn- und Umsatzwachstum von 3.6% bzw. 3.9% prognostiziert. Der Gewinn pro Aktie wird voraussichtlich wachsen um 3.7% pro Jahr. Die Eigenkapitalrendite wird in 3 Jahren voraussichtlich 5.3% betragen.

Wichtige Informationen

3.6%

Wachstumsrate der Gewinne

3.7%

EPS-Wachstumsrate

Pharmaceuticals Gewinnwachstum	11.6%
Wachstumsrate der Einnahmen	3.9%
Zukünftige Eigenkapitalrendite	5.3%
Analystenabdeckung	Good
Zuletzt aktualisiert	10 Mar 2025

Jüngste Aktualisierungen zum künftigen Wachstum

Results: Eisai Co., Ltd. Exceeded Expectations And The Consensus Has Updated Its Estimates

Feb 11

Results: Eisai Co., Ltd. Exceeded Expectations And The Consensus Has Updated Its Estimates

Nov 12

Recent updates

Results: Eisai Co., Ltd. Exceeded Expectations And The Consensus Has Updated Its Estimates

Feb 11

Eisai (TSE:4523) Has Announced A Dividend Of ¥80.00

Jan 28

Eisai (TSE:4523) Is Due To Pay A Dividend Of ¥80.00

Jan 14

Here's Why Eisai (TSE:4523) Can Manage Its Debt Responsibly

Jan 13

Eisai Co., Ltd.'s (TSE:4523) Share Price Matching Investor Opinion

Dec 26

Eisai (TSE:4523) Is Paying Out A Dividend Of ¥80.00

Dec 05

Eisai (TSE:4523) Is Paying Out A Dividend Of ¥80.00

Nov 21

Earnings Troubles May Signal Larger Issues for Eisai (TSE:4523) Shareholders

Nov 15

Results: Eisai Co., Ltd. Exceeded Expectations And The Consensus Has Updated Its Estimates

Nov 12

Is Eisai (TSE:4523) Using Too Much Debt?

Oct 15

Eisai (TSE:4523) Is Paying Out A Dividend Of ¥80.00

Sep 20

Eisai (TSE:4523) Has Affirmed Its Dividend Of ¥80.00

Sep 05

Eisai (TSE:4523) Has Affirmed Its Dividend Of ¥80.00

Aug 08

Eisai (TSE:4523) Is Due To Pay A Dividend Of ¥80.00

Jul 25

Is Eisai (TSE:4523) A Risky Investment?

Jul 11

Eisai (TSE:4523) Has Affirmed Its Dividend Of ¥80.00

Jul 11

Eisai Co., Ltd.'s (TSE:4523) P/E Is On The Mark

Jun 10

Here's Why Eisai (TSE:4523) Can Manage Its Debt Responsibly

Apr 11

Gewinn- und Umsatzwachstumsprognosen

TSE:4523 - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (JPY Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
3/31/2027	854,182	55,246	52,881	86,175	15
3/31/2026	818,988	52,278	46,100	77,678	16
3/31/2025	771,163	45,118	67,838	114,149	16
12/31/2024	791,660	58,792	1,672	18,856	N/A
9/30/2024	753,221	40,970	7,189	27,613	N/A
6/30/2024	733,845	32,648	13,901	34,771	N/A
3/31/2024	741,751	42,406	31,170	55,993	N/A
12/31/2023	749,460	45,421	35,701	61,925	N/A
9/30/2023	759,329	48,096	20,569	46,335	N/A
6/30/2023	757,075	48,874	-20,313	6,924	N/A
3/31/2023	744,402	55,432	-36,331	-1,772	N/A
12/31/2022	737,098	26,705	-17,149	18,648	N/A
9/30/2022	752,500	32,233	-8,913	30,329	N/A
6/30/2022	741,594	32,690	94,326	135,806	N/A
3/31/2022	756,226	47,954	77,123	117,590	N/A
12/31/2021	712,935	57,311	85,128	124,927	N/A
9/30/2021	691,250	62,508	80,215	123,618	N/A
6/30/2021	679,253	59,855	8,589	49,533	N/A
3/31/2021	645,942	42,119	35,709	73,853	N/A
12/31/2020	707,888	93,682	52,352	95,670	N/A
9/30/2020	713,400	120,571	77,080	112,990	N/A
6/30/2020	707,203	124,523	81,101	116,904	N/A
3/31/2020	695,621	121,767	52,556	102,782	N/A
12/31/2019	661,646	96,659	21,665	72,461	N/A
9/30/2019	631,974	57,725	12,273	62,240	N/A
6/30/2019	643,531	72,747	38,725	87,299	N/A
3/31/2019	642,834	63,386	76,092	103,714	N/A
12/31/2018	627,367	63,714	151,104	171,330	N/A
9/30/2018	625,106	65,679	N/A	186,973	N/A
6/30/2018	611,499	54,347	N/A	165,689	N/A
3/31/2018	600,054	51,845	N/A	149,649	N/A
12/31/2017	569,814	29,048	N/A	72,041	N/A
9/30/2017	554,276	30,269	N/A	61,644	N/A
6/30/2017	544,027	29,425	N/A	76,929	N/A
3/31/2017	539,097	39,358	N/A	75,851	N/A
12/31/2016	530,696	55,031	N/A	76,725	N/A
9/30/2016	542,313	71,812	N/A	78,627	N/A
6/30/2016	545,602	69,227	N/A	69,710	N/A
3/31/2016	547,922	54,933	N/A	95,617	N/A
12/31/2015	566,435	44,886	N/A	96,347	N/A
9/30/2015	554,912	43,871	N/A	82,653	N/A
6/30/2015	554,885	43,021	N/A	89,212	N/A
3/31/2015	548,465	43,254	N/A	76,022	N/A
12/31/2014	560,795	40,152	N/A	67,972	N/A
9/30/2014	561,938	15,717	N/A	81,637	N/A
6/30/2014	578,945	29,225	N/A	81,339	N/A
3/31/2014	600,363	32,955	N/A	85,687	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: 4523Das prognostizierte Gewinnwachstum (3.6% pro Jahr) liegt über der Sparquote (0.4%).

Ertrag vs. Markt: 4523Die Erträge des Unternehmens (3.6% pro Jahr) werden voraussichtlich langsamer wachsen als der Markt JP (8% pro Jahr).

Hohe Wachstumserträge: 4523Die Erträge des Unternehmens werden voraussichtlich steigen, jedoch nicht deutlich.

Einnahmen vs. Markt: 4523Die Einnahmen des Unternehmens (3.9% pro Jahr) werden voraussichtlich langsamer wachsen als der Markt JP (4.2% pro Jahr).

Hohe Wachstumseinnahmen: 4523Die Einnahmen des Unternehmens (3.9% pro Jahr) werden voraussichtlich langsamer wachsen als 20% pro Jahr.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: 4523Die Eigenkapitalrendite des Unternehmens wird in 3 Jahren voraussichtlich niedrig sein (5.3%).

Wachstumsunternehmen entdecken

Unternehmensanalyse und Finanzdaten Status

Daten	Zuletzt aktualisiert (UTC-Zeit)
Unternehmensanalyse	2025/03/23 02:05
Aktienkurs zum Tagesende	2025/03/21 00:00
Gewinne	2024/12/31
Jährliche Einnahmen	2024/03/31

Datenquellen

Die in unserer Unternehmensanalyse verwendeten Daten stammen von S&P Global Market Intelligence LLC. Die folgenden Daten werden in unserem Analysemodell verwendet, um diesen Bericht zu erstellen. Die Daten sind normalisiert, was zu einer Verzögerung bei der Verfügbarkeit der Quelle führen kann.

Paket	Daten	Zeitrahmen	Beispiel US-Quelle ^*
Finanzdaten des Unternehmens	10 Jahre	Gewinn- und Verlustrechnung Kapitalflussrechnung Bilanz	SEC-Formular 10-K SEC-Formular 10-Q
Konsensschätzungen der Analysten	+3 Jahre	Finanzielle Vorausschau Kursziele der Analysten	Analysten Research Berichte Blue Matrix
Marktpreise	30 Jahre	Aktienkurse Dividenden, Splits und Aktionen	ICE-Marktdaten SEC-Formular S-1
Eigentümerschaft	10 Jahre	Top-Aktionäre Insiderhandel	SEC-Formular 4 SEC-Formular 13D
Verwaltung	10 Jahre	Das Führungsteam Direktorium	SEC-Formular 10-K SEC-Formular DEF 14A
Wichtige Entwicklungen	10 Jahre	Ankündigungen des Unternehmens	SEC-Formular 8-K

* Beispiel für US-Wertpapiere, für nicht-US-amerikanische Wertpapiere werden gleichwertige regulatorische Formulare und Quellen verwendet.

Sofern nicht anders angegeben, beziehen sich alle Finanzdaten auf einen Jahreszeitraum, werden aber vierteljährlich aktualisiert. Dies wird als Trailing Twelve Month (TTM) oder Last Twelve Month (LTM) Daten bezeichnet. Erfahren Sie mehr.

Analysemodell und Schneeflocke

Einzelheiten zum Analysemodell, das zur Erstellung dieses Berichts verwendet wurde, finden Sie auf unserer Github-Seite. Wir haben auch Anleitungen zur Verwendung unserer Berichte und Tutorials auf Youtube.

Erfahren Sie mehr über das Weltklasse-Team, das das Simply Wall St-Analysemodell entworfen und entwickelt hat.

Metriken für Industrie und Sektor

Unsere Branchen- und Sektionskennzahlen werden alle 6 Stunden von Simply Wall St berechnet. Details zu unserem Verfahren finden Sie auf Github.

Analysten-Quellen

Eisai Co., Ltd. wird von 26 Analysten beobachtet. 16 dieser Analysten hat die Umsatz- oder Gewinnschätzungen übermittelt, die als Grundlage für unseren Bericht dienen. Die von den Analysten übermittelten Daten werden im Laufe des Tages aktualisiert.

Analyst	Einrichtung
Atsushi Seki	Barclays
Koichi Mamegano	BofA Global Research
Aaron Ho	CFRA Equity Research

Eisai Zukünftiges Wachstum

Future Kriterienprüfungen 1/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

Results: Eisai Co., Ltd. Exceeded Expectations And The Consensus Has Updated Its Estimates

Price target decreased by 7.7% to JP¥6,103

Results: Eisai Co., Ltd. Exceeded Expectations And The Consensus Has Updated Its Estimates

Consensus EPS estimates increase by 10%, revenue downgraded

Recent updates

Upcoming dividend of JP¥80.00 per share

Eisai (TSE:4523) Is Due To Pay A Dividend Of ¥80.00

Eisai Co., Ltd. to Report Q2, 2026 Results on Nov 05, 2025

Eisai Co., Ltd. to Report Fiscal Year 2025 Results on May 15, 2025

Eisai (TSE:4523) Will Pay A Dividend Of ¥80.00

Eisai Co., Ltd. and Biogen Inc. Reaffirms Positive Opinion for Lecanemab in Early Alzheimer's Disease

Now 20% undervalued after recent price drop

Eisai (TSE:4523) Will Pay A Dividend Of ¥80.00

Results: Eisai Co., Ltd. Exceeded Expectations And The Consensus Has Updated Its Estimates

Third quarter 2025 earnings: EPS and revenues exceed analyst expectations

Now 20% undervalued after recent price drop

Eisai (TSE:4523) Has Announced A Dividend Of ¥80.00

Eisai Co., Ltd. and Biogen Inc. Announce FDA Approves LEQEMBI (lecanemab-irmb) IV Maintenance Dosing for the Treatment of Early Alzheimer's Disease

Eisai Announces FDA Approval for Leqembi in US

Merck and Eisai Provide Update on Phase 3 LEAP-015 Trial Evaluating KEYTRUDA (Pembrolizumab) Plus LENVIMA (Lenvima) in Combination with Chemotherapy in Patients with Certain Types of Gastroesophageal Adenocarcinoma

Price target decreased by 7.7% to JP¥6,103

Eisai (TSE:4523) Is Due To Pay A Dividend Of ¥80.00

Eisai Co., Ltd. and Biogen Inc. Announces FDA Accepts LEQEMBI (lecanemab-irmb) Biologics License Application for Subcutaneous Maintenance Dosing for the Treatment of Early Alzheimer's Disease

Here's Why Eisai (TSE:4523) Can Manage Its Debt Responsibly

Eisai Co., Ltd.'s (TSE:4523) Share Price Matching Investor Opinion

Eisai Co., Ltd. and Biogen Inc. Announces Approval of ''LEQEMBI" (Lecanemab) for the Treatment of Early Alzheimer's Disease in Mexico

Eisai (TSE:4523) Is Paying Out A Dividend Of ¥80.00

Eisai Co., Ltd. and Biogen Inc. Announce "LEQEMBI®" (Lecanemab) for the Treatment of Alzheimer's Disease Launched in South Korea

Eisai (TSE:4523) Is Paying Out A Dividend Of ¥80.00

First half dividend of JP¥80.00 announced

Earnings Troubles May Signal Larger Issues for Eisai (TSE:4523) Shareholders

Eisai Co., Ltd. and Biogen Inc. Receive Positive Opinion from CHMP in European Union for Lecanemab in Early Alzheimer’s Disease

Results: Eisai Co., Ltd. Exceeded Expectations And The Consensus Has Updated Its Estimates

Second quarter 2025 earnings: EPS and revenues exceed analyst expectations

Eisai Completes Rolling BLA Submission for Subcutaneous Maintenance Dosing of Leqembi® (lecanemab-irmb) in the US

Eisai Co., Ltd. and Biogen Inc. Completes Rolling Submission to US FDA for LEQEMBI Biologics License Application for Subcutaneous Maintenance Dosing

Eisai Co., Ltd. Presents Latest Clinical Findings Suggesting Inhibition of Tau Propagation by Anti-MTBR Tau Antibody E2814 at the 17th Clinical Trials on Alzheimer's Disease Conference

Is Eisai (TSE:4523) Using Too Much Debt?

Upcoming dividend of JP¥80.00 per share

Eisai (TSE:4523) Is Paying Out A Dividend Of ¥80.00

Merck and Eisai Announce Results from the First Interim Analysis of the Phase 3 LEAP-012 Trial Evaluating KEYTRUDA® (Pembrolizumab)

Eisai (TSE:4523) Has Affirmed Its Dividend Of ¥80.00

Eisai Co., Ltd. Accelerates Progress in Oncology Research with New Data At Esmo Congress 2024

BioArctic AB (Publ) Partner Eisai Announces Leqembi (Lecanemab) Authorized for Early Alzheimer's Disease in Great Britain

Eisai (TSE:4523) Has Affirmed Its Dividend Of ¥80.00

New minor risk - Earnings quality

First quarter 2025 earnings: EPS and revenues exceed analyst expectations

Investor sentiment deteriorates as stock falls 17%

Eisai Co., Ltd. and Biogen Inc. Announces New Clinical Data Demonstrates Three Years of Continuous Treatment with Dual-Acting Leqemab (Lecanemab-Irmb) Continues to Significantly Benefit Early Alzheimer's Disease Patients Presented at the Alzheimer's Association International Conference

New minor risk - Share price stability

Eisai Provides Update on Regulatory Review of Lecanemab for Early Alzheimer's Disease in the European Union

Eisai (TSE:4523) Is Due To Pay A Dividend Of ¥80.00

Eisai Co. Ltd Announces To Present Latest Findings on Its Alzheimer's Disease Pipeline and Research

Eisai Announces Approval for the Treatment of Alzheimer's Disease in Israel

Is Eisai (TSE:4523) A Risky Investment?

Eisai (TSE:4523) Has Affirmed Its Dividend Of ¥80.00

Final dividend of JP¥80.00 announced

High number of new directors

Eisai Co., Ltd. and Biogen Inc. Announces Launch of Leqembi in China

Full year 2024 earnings: EPS exceeds analyst expectations

Eisai Co., Ltd.'s (TSE:4523) P/E Is On The Mark

Consensus EPS estimates increase by 10%, revenue downgraded

Eisai Co., Ltd. (TSE:4523) announces an Equity Buyback for 6,500,000 shares, representing 2.26% for ¥30,000 million.

Eisai Initiates Rolling Biologics License Application to US FDA for LEQEMBI® (Lecanemab-Irmb) for Subcutaneous Maintenance Dosing for the Treatment of Early Alzheimer's Disease Under the Fast Track Status

High number of new directors

Here's Why Eisai (TSE:4523) Can Manage Its Debt Responsibly

Eisai Completes Submission of Leqembi® (Lecanemab-Irmb) Supplemental Biologics License Application for Iv Maintenance Dosing for the Treatment of Early Alzheimer's Disease to the U.S. FDA

Upcoming dividend of JP¥80.00 per share

BioArctic AB (publ) and its Partner Eisai Present New Data on Lecanemab at 2024 International Conference on Alzheimer's and Parkinson's Diseases and Related Neurological Disorders

Now 21% overvalued

Eisai Co., Ltd. to Report Q3, 2025 Results on Feb 07, 2025

Eisai Receives Approval in Japan for Injection Formulation of Antiepileptic Drug Fycompa®

Third quarter 2024 earnings: EPS and revenues miss analyst expectations

Eisai Announces Leqembi Approval for the Treatment of Alzheimer's Disease in China

Eisai Co., Ltd. Announces Launch of LEQEMBI in Japan on December 20

Merck and Eisai Provide Update on Phase 3 Leap-001 Trial Evaluating (Pembrolizumab) Plus Lenvima(R) (Lenvatinib) as First-Line Treatment for Patients with Advanced or Recurrent Endometrial Carcinoma